OBD
NEUTRALOxford BioDynamics Publishes 2025 Annual Report
The healthcare diagnostics company has published its annual report for the year ended 30 September 2025.
Oxf BioDynamics
0.3000GBX
7.14%
Market Cap
12.87M
Volume
47.73M
176% of avg
P/E Ratio
-75.00
EPS (TTM)
-0
Beta
-0.64
Day Range
0.2715p - 0.3185p
52 Week Range
0.2030p0.3000p0.8500p
0.3000p
Upcoming Events
26 January 2026
Annual General Meeting
OBD
BADOxford BioDynamics Reports Revenue Growth Amid Ongoing Losses in FY2025 Results
The biotechnology firm reported doubled revenue and test orders, but faces ongoing losses and cash burn. A recent £7m fundraise highlights continued reliance on external financing amid material uncertainties.
OBD
NEUTRALOxford BioDynamics Announces Notice of Results
The diagnostics company has announced it will release its annual results on 16 December 2025.
OBD
NEUTRALOxford BioDynamics Provides Update on EpiSwitch PSE Test
The diagnostics company provides an update on its EpiSwitch PSE test, noting continued sales growth in the US and UK private healthcare market.
OBD
NEUTRALOxford BioDynamics Announces Shareholding Change
The diagnostics company has announced a change in shareholding, with Vulpes Investment Management Pte Ltd increasing its stake to 14.42%.
OBD
NEUTRALOxford BioDynamics Provides Regulatory Update
The healthcare diagnostics company has announced a regulatory filing regarding a change in shareholding.
OBD
NEUTRALOxford BioDynamics Plc Provides Regulatory Update
The diagnostics company has announced a regulatory filing regarding a change in shareholding.
OBD
NEUTRALOxford BioDynamics Plc Announces Holding(s) in Company
The healthcare diagnostics company has received a notification of a change in major shareholding.
OBD
NEUTRALOxford BioDynamics Plc Announces Holding(s) in Company
The healthcare diagnostics company has announced a change in major shareholding, with Unicorn Asset Management Limited now holding 12.86% of the voting rights.
OBD
NEUTRALOxford BioDynamics Grants Share Options to Directors and PDMRs
The diagnostics company has granted share options to its senior management team.